Targeting treatment resistance in cervical cancer: A new avenue for senolytic therapies.

Autor: Meyer M; Department of Physiological Sciences, Stellenbosch University, Stellenbosch, South Africa., Fourie C; Department of Physiological Sciences, Stellenbosch University, Stellenbosch, South Africa., van der Merwe H; Department of Obstetrics and Gynaecology, Stellenbosch University Medical Campus, Cape Town, South Africa., Botha H; Department of Obstetrics and Gynaecology, Stellenbosch University Medical Campus, Cape Town, South Africa., Engelbrecht AM; Department of Physiological Sciences, Stellenbosch University, Stellenbosch, South Africa. Electronic address: ame@sun.ac.za.
Jazyk: angličtina
Zdroj: Advances in medical sciences [Adv Med Sci] 2024 Nov 14. Date of Electronic Publication: 2024 Nov 14.
DOI: 10.1016/j.advms.2024.11.001
Abstrakt: Cervical cancer poses a significant global health challenge, particularly impacting women in economically developing nations. This disparity stems from a combination of factors, including inadequate screening infrastructure and resource limitations. However, the foremost contributor is the widespread lack of awareness and limited accessibility to Human Papillomavirus (HPV) vaccination, which is a key preventative measure against cervical cancer development. Despite advancements in cervical cancer prevention, treatment resistance remains a major hurdle in achieving improved patient outcomes. Cellular senescence, specifically the senescence-associated secretory phenotype (SASP) and its bidirectional relationship with the immune system, has been implicated in resistance to conventional cervical cancer chemotherapy treatments. The exact mechanisms by which this state of growth arrest and the associated changes in immune regulation contribute to cervical cancer progression and the associated drug resistance are not entirely understood. This underscores the necessity for innovative strategies to address the prevalence of treatment-resistant cervical cancer, with one promising avenue being the utilisation of senolytics. Senolytics are agents that have promising efficacy in clearing senescent cells from tumour tissues, however neither the utilisation of senolytics for addressing senescence-induced treatment resistance nor the potential integration of immunotherapy as senolytic agents in cervical cancer treatment has been explored to date. This review provides a concise overview of the mechanisms underlying senescence induction and the pivotal role of the immune system in this process. Additionally, it explores various senolytic approaches that hold significant potential for advancing cervical cancer research.
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024. Published by Elsevier B.V.)
Databáze: MEDLINE
Externí odkaz: